Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)

ConditionsAtrial Fibrillation HFpEF - Heart Failure With Preserved Ejection Fraction

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-80

SponsorThe First Affiliated Hospital with Nanjing Medical University

About this trial

To investigate whether RFCA is superior to AADs in AF patients with HFpEF on the basis of optimized anti-heart-failure drug therapy regarding their longterm clinical outcomes.

Eligibility criteria

Qualifiers

Symptomatic paroxysmal or persistent atrial fibrillation

CHADS2-VASc score≥ 2

Conform to the diagnosis of HFpEF

NYHA II-IV level;

Disqualifiers

A life expectancy below 2 years due to any non-cardiovascular condition

Reversible atrial fibrillation, such as hyperthyroidism or hypokalemia-related atrial fibrillation

Prior atrial fibrillation ablation

Left atrial size≥ 55 mm

Trial design

Treatments tested in this trial

Radiofrequency catheter ablation (RFCA)
Medical Therapy

Treatment groups

436 Participants

are divided into 2 treatment groups

Sponsors and collaborators

The First Affiliated Hospital with Nanjing Medical University

Lead sponsor

Source ClinicalTrials.gov